INmune Bio Inc. (INMB) PT Lowered to $14 at BTIG
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts INMB Hot Sheet
Price: $1.33 --0%
Rating Summary:
7 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 2
Rating Summary:
7 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 2
Join SI Premium – FREE
BTIG analyst Thomas Shrader lowered the price target on INmune Bio Inc. (NASDAQ: INMB) to $14.00 (from $31.00) while maintaining a Buy rating.
You May Also Be Interested In
- Morgan Stanley Downgrades HubSpot Inc (HUBS) to Equalweight
- Primoris Services Corporation (PRIM) PT Lowered to $110 at Needham
- Snap Inc (SNAP) PT Lowered to $8 at Barclays
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
